CytomX Therapeutics, Inc.

CTMX · NASDAQ
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Activities
Net Income$32-$1-$99-$84
Dep. & Amort.$2$2$6$3
Deferred Tax$0$0$0$0
Stock-Based Comp.$8$0$0$13
Change in WC-$126-$63-$31-$55
Other Non-Cash-$1$5$13$3
Operating Cash Flow-$86-$56-$111-$119
Investing Activities
PP&E Inv.-$0-$1-$2-$2
Net Acquisitions$0$0$0-$24
Inv. Purchases-$155-$425$0-$100
Inv. Sales/Matur.$256$275$100$124
Other Inv. Act.$0$0$0$24
Investing Cash Flow$100-$151$98$22
Financing Activities
Debt Repay.$0$0$0$0
Stock Issued$7$30$1$108
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$1$0$0$3
Financing Cash Flow$8$30$1$110
Forex Effect$0$0$0$0
Net Chg. in Cash$21-$176-$12$14
Supplemental Information
Beg. Cash$18$194$206$193
End Cash$39$17$194$206
Free Cash Flow-$87-$57-$113-$121
CytomX Therapeutics, Inc. (CTMX) Financial Statements & Key Stats | AlphaPilot